486 related articles for article (PubMed ID: 31408463)
1. The oncoprotein DEK affects the outcome of PARP1/2 inhibition during mild replication stress.
Ganz M; Vogel C; Czada C; Jörke V; Gwosch EC; Kleiner R; Pierzynska-Mach A; Zanacchi FC; Diaspro A; Kappes F; Bürkle A; Ferrando-May E
PLoS One; 2019; 14(8):e0213130. PubMed ID: 31408463
[TBL] [Abstract][Full Text] [Related]
2. High-affinity interaction of poly(ADP-ribose) and the human DEK oncoprotein depends upon chain length.
Fahrer J; Popp O; Malanga M; Beneke S; Markovitz DM; Ferrando-May E; Bürkle A; Kappes F
Biochemistry; 2010 Aug; 49(33):7119-30. PubMed ID: 20669926
[TBL] [Abstract][Full Text] [Related]
3. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
Zhang L; Li DQ
Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribosyl)ation of TIMELESS limits DNA replication stress and promotes stalled fork protection.
Rageul J; Lo N; Phi AL; Patel JA; Park JJ; Kim H
Cell Rep; 2024 Mar; 43(3):113845. PubMed ID: 38393943
[TBL] [Abstract][Full Text] [Related]
5. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery.
Gamble MJ; Fisher RP
Nat Struct Mol Biol; 2007 Jun; 14(6):548-55. PubMed ID: 17529993
[TBL] [Abstract][Full Text] [Related]
6. The human oncoprotein and chromatin architectural factor DEK counteracts DNA replication stress.
Deutzmann A; Ganz M; Schönenberger F; Vervoorts J; Kappes F; Ferrando-May E
Oncogene; 2015 Aug; 34(32):4270-7. PubMed ID: 25347734
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
[TBL] [Abstract][Full Text] [Related]
8. The DEK Oncoprotein Functions in Ovarian Cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract][Full Text] [Related]
9. The Complexity of DEK Signaling in Cancer Progression.
Teng Y; Lang L; Jauregui CE
Curr Cancer Drug Targets; 2018; 18(3):256-265. PubMed ID: 28530531
[TBL] [Abstract][Full Text] [Related]
10. DEK oncogene is overexpressed during melanoma progression.
Riveiro-Falkenbach E; Ruano Y; García-Martín RM; Lora D; Cifdaloz M; Acquadro F; Ballestín C; Ortiz-Romero PL; Soengas MS; Rodríguez-Peralto JL
Pigment Cell Melanoma Res; 2017 Mar; 30(2):194-202. PubMed ID: 27893188
[TBL] [Abstract][Full Text] [Related]
11. High speed of fork progression induces DNA replication stress and genomic instability.
Maya-Mendoza A; Moudry P; Merchut-Maya JM; Lee M; Strauss R; Bartek J
Nature; 2018 Jul; 559(7713):279-284. PubMed ID: 29950726
[TBL] [Abstract][Full Text] [Related]
12. Differential and Concordant Roles for Poly(ADP-Ribose) Polymerase 1 and Poly(ADP-Ribose) in Regulating WRN and RECQL5 Activities.
Khadka P; Hsu JK; Veith S; Tadokoro T; Shamanna RA; Mangerich A; Croteau DL; Bohr VA
Mol Cell Biol; 2015 Dec; 35(23):3974-89. PubMed ID: 26391948
[TBL] [Abstract][Full Text] [Related]
13. Bacterial Growth Inhibition Screen (BGIS) identifies a loss-of-function mutant of the DEK oncogene, indicating DNA modulating activities of DEK in chromatin.
Guo H; Prell M; Königs H; Xu N; Waldmann T; Hermans-Sachweh B; Ferrando-May E; Lüscher B; Kappes F
FEBS Lett; 2021 May; 595(10):1438-1453. PubMed ID: 33686684
[TBL] [Abstract][Full Text] [Related]
14. The unique DEK oncoprotein in women's health: A potential novel biomarker.
de Albuquerque Oliveira AC; Kappes F; Martins DBG; de Lima Filho JL
Biomed Pharmacother; 2018 Oct; 106():142-148. PubMed ID: 29957464
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation.
Min W; Bruhn C; Grigaravicius P; Zhou ZW; Li F; Krüger A; Siddeek B; Greulich KO; Popp O; Meisezahl C; Calkhoven CF; Bürkle A; Xu X; Wang ZQ
Nat Commun; 2013; 4():2993. PubMed ID: 24356582
[TBL] [Abstract][Full Text] [Related]
16. The DEK oncogene activates VEGF expression and promotes tumor angiogenesis and growth in HIF-1α-dependent and -independent manners.
Zhang Y; Liu J; Wang S; Luo X; Li Y; Lv Z; Zhu J; Lin J; Ding L; Ye Q
Oncotarget; 2016 Apr; 7(17):23740-56. PubMed ID: 26988756
[TBL] [Abstract][Full Text] [Related]
17. The nuclear DEK interactome supports multi-functionality.
Smith EA; Krumpelbeck EF; Jegga AG; Prell M; Matrka MM; Kappes F; Greis KD; Ali AM; Meetei AR; Wells SI
Proteins; 2018 Jan; 86(1):88-97. PubMed ID: 29082557
[TBL] [Abstract][Full Text] [Related]
18. Mitotic functions of poly(ADP-ribose) polymerases.
Slade D
Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
[TBL] [Abstract][Full Text] [Related]
19. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.
Kappes F; Fahrer J; Khodadoust MS; Tabbert A; Strasser C; Mor-Vaknin N; Moreno-Villanueva M; Bürkle A; Markovitz DM; Ferrando-May E
Mol Cell Biol; 2008 May; 28(10):3245-57. PubMed ID: 18332104
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.
Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Ahmed RM; Denman M; Steele CD; Tarabichi M; Roy E; Davies LR; Manji J; Cristalli C; Scotlandi K; Pillay N; Strauss SJ; Mittnacht S
Nat Commun; 2021 Dec; 12(1):7064. PubMed ID: 34862364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]